NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

NOVO.B.DK

245.7

-0.87%↓

GMAB.DK

1,743

-1.64%↓

HLUNB.DK

42.96

-0.56%↓

ZEAL.DK

305.3

-0.03%↓

AMBUB.DK

66.25

-2.72%↓

Search

Coloplast A-S (Class B)

Fermé

419.3 -0.43

Résumé

Variation du prix de l'action

24h

Actuel

Min

417.9

Max

423.1

Chiffres clés

By Trading Economics

Revenu

522M

1.4B

Ventes

83M

7B

P/E

Moyenne du Secteur

24.492

60.328

BPA

6.32

Rendement du dividende

5.28

Marge bénéficiaire

19.835

Employés

16,983

EBITDA

309M

2.3B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

5.28%

2.24%

Prochains Résultats

12 mai 2026

Date du Prochain Dividende

20 mai 2026

Date du Prochain Détachement de Dividende

18 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-21B

98B

Ouverture précédente

419.73

Clôture précédente

419.3

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 00:00 UTC

Résultats

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 avr. 2026, 00:00 UTC

Résultats

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 avr. 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 avr. 2026, 23:13 UTC

Acquisitions, Fusions, Rachats

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 avr. 2026, 22:33 UTC

Résultats

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 avr. 2026, 22:17 UTC

Résultats

PLS Executed Offtake Agreement With Ronbay

23 avr. 2026, 22:17 UTC

Résultats

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 avr. 2026, 22:16 UTC

Résultats

PLS Commences Commissioning of Midstream Demonstration Plant

23 avr. 2026, 22:15 UTC

Résultats

PLS Group Reaffirms FY26 Guidance for All Metrics

23 avr. 2026, 22:14 UTC

Résultats

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 avr. 2026, 22:14 UTC

Résultats

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 avr. 2026, 22:13 UTC

Résultats

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 avr. 2026, 22:12 UTC

Résultats

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 avr. 2026, 22:12 UTC

Résultats

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 avr. 2026, 22:11 UTC

Résultats

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 avr. 2026, 22:10 UTC

Résultats

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 avr. 2026, 22:09 UTC

Résultats

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 avr. 2026, 22:08 UTC

Résultats

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 avr. 2026, 22:04 UTC

Résultats

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 avr. 2026, 21:56 UTC

Market Talk
Résultats

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 avr. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 avr. 2026, 21:27 UTC

Résultats

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 avr. 2026, 21:25 UTC

Résultats

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 avr. 2026, 21:24 UTC

Résultats

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 avr. 2026, 21:24 UTC

Résultats

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 avr. 2026, 21:21 UTC

Résultats

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 avr. 2026, 21:21 UTC

Résultats

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Comparaison

Variation de prix

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat